AbbVie’s $8.7B neuro gambit; Landmark sickle cell approvals; Roche buys a GLP-1 company; Endpoints 100 biotech survey; and more

Ab­b­Vie’s $8.7B neu­ro gam­bit; Land­mark sick­le cell ap­provals; Roche buys a GLP-1 com­pa­ny; End­points 100 biotech sur­vey; and more Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here. What a week! News has tru­ly been fir­ing on all cylin­ders, and our team is proud to present not just the break­ing sto­ries but sec­ond-day analy­ses of what they mean. If you’re in­to hema­tol­ogy, do check the web­site over the week­end for Max Gel­man and Lei Lei Wu’s live cov­er­age of ASH. Al­ter­na­tive­ly, we will catch you up on Mon­day. Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.